HOME >> BIOLOGY >> NEWS
Poetically Timed With Spring, Budding Yeast Yield Possible Insight Into Male Fertility--And Infertility

ores, which carry the genes leading to offspring, have a lot in common with sperm.

Both spore and sperm are created from other cells only after undergoing a complex process known as meiosis, in which a cell's DNA replicates and then undergoes two steps of division. Spore and sperm also have unique shapes relative to the cells that created them. In addition, two matured yeast spores can fuse to produce progeny just as sperm and egg fuse to produce offspring.

Spore and sperm are also both susceptible to being blocked in mid development, just before the cells from which they are produced undergo the first of the two divisions of their DNA. This interruption occurs at a stage of meiosis called pachytene and, in most cases, is temporary and beneficial, serving as a period during which the cell can repair any damage that may have occurred up to that point in development.

At least in human sperm, however, interruption can be permanent, preventing the further development of the cell--and thereby causing sterility, as in testicular maturation arrest.

In the UCSF study, the researchers determined that a gene, known as NDT80, plays a critical role in this pachytene stage of meiosis in yeast. They found that the NDT80 gene encodes the critical protein that acts to stimulate the synthesis of a set of proteins known as cyclins, which spark entry into DNA division. They also determined that the Ndt80 protein is responsible for the synthesis of another set of proteins, which contribute to the unique shape of the spore.

Finally, the authors showed that Ndt80 is itself controlled by a so-called "check point" protein called Rad17. Normally, check point proteins play the invaluable role of stalling further cell development when there are indications of damage, until repair has taken place. If a precursor cell's DNA has somehow accum
'"/>

Contact: Jennifer O'Brien
jobrien@itsa.ucsf.edu
(415) 476-2557
University of California - San Francisco
23-Apr-1998


Page: 1 2 3 4

Related biology news :

1. Budding viral hijackers may co-opt cell machinery for the getaway
2. Yeast mutations offer window into human disease
3. Yeast model yields insights into Parkinsons disease
4. Yeast helps researchers better understand Parkinsons mystery
5. Yeast, wormwood & bacterial genes combine in microbial factory to make antimalarial drug
6. Yeast genomes reveal new sites of gene control
7. Yeast research targets drug resistance battle
8. Yeast underscores complexity of genetic variation between people
9. Yeast Provides Evidence For Continuous Membrane Theory
10. Yeast Rises To A New Occasion
11. Bakers Yeast Causes Chemical Reactions And Sweet Smelling Labs

Post Your Comments:
(Date:5/20/2013)... 2013) - A novel vaccine study from ... research that will be unveiled at the American Association ... meeting takes place Monday, May 20 - Wednesday, May ... , "The main goal of a vaccine is ... pathogen that causes the disease", explained Dr. Hemachand Tummala, ...
(Date:5/19/2013)... at the University of California, Davis have engineered a ... for light. They report their findings today at ... Microbiology. , "In this work, we used synthetic biology ... carbon dioxide and light energy for growth) cyanobacterial metabolism ... Jordan McEwen, the lead researcher on the study. ...
(Date:5/17/2013)... (May 18, 2013) The AGA Research Foundation announced ... the relationship between the gut microbiota, one of today,s ... disease. , The AGA Research Awards Panel selected ... Massachusetts General Hospital and Harvard Medical School, Boston, as ... Dr. Chan will receive $25,000 of funding, commencing in ...
Breaking Biology News(10 mins):Germ-fighting vaccine system makes great strides in delivery 2New gut microbiome research to explore red meat -- colorectal cancer pathway 2
(Date:5/21/2013)... Alpha Source, Inc., a Wisconsin-based ... exhibiting for the 13th consecutive year at the ... 2013 Conference and Expo. The conference brings together ... healthcare technologies. This year’s event will be held ... , The three-day event draws over 1,500 healthcare ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
(Date:5/21/2013)... As the R&D sector becomes increasingly ... industry to deliver better products, faster. Collaborations between ... often means turning big ideas into reality, within ... with Sensidose AB and Recipharm, is one example ... market sooner. The partnership resulted in the development ...
(Date:5/21/2013)... ROCKVILLE, Md. , May 21, 2013 /PRNewswire/ ... "Phase 1 study of margetuximab (MGAH22), an Fc-modified ... solid tumors expressing the HER2 oncoprotein," will be ... American Society of Clinical Oncology during the Developmental ... June 3 at 4:15 – 4:30 PM.  The ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: